Physician profile
Adam Mues
NPI 1871700054
$13,574.60
in general payments reported to CMS, 2019-2025
24 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $121 · 2021: $13K · 2022: $21.52 · 2023: $20.25 · 2024: $559 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $658 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $657.93 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,497.01 | 2020-2021 | |
| Medtronic USA, INC. | $189.04 | 2019-2020 | |
| Teleflex LLC | $165.09 | 2024 | Urolift |
| Janssen Biotech, INC. | $150.40 | 2024-2025 | Erleada, Carvykti, Talvey |
| Medtronic, INC. | $102.30 | 2021-2024 | Interstim |
| Astrazeneca Pharmaceuticals LP | $52.16 | 2024-2025 | Tagrisso, Imfinzi |
| Coloplast Corp | $49.82 | 2021-2023 | Altis |
| Neotract INC. | $39.83 | 2020 | |
| Dendreon Pharmaceuticals LLC | $33.87 | 2025 | Provenge |
| Stemline Therapeutics INC. | $30.63 | 2024 | Elzonris, Orserdu |
| Mirati Therapeutics, INC. | $26.49 | 2024 | Krazati |
| Astellas Pharma US INC | $23.15 | 2025 | Vyloy |
| Boston Scientific Corporation | $22.42 | 2024 | Advantage System |
| Cook Medical LLC | $22.14 | 2024 | S~Curve |
| Olympus America INC. | $21.52 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $19.83 | 2025 | Airseal |
| Daiichi Sankyo INC. | $17.60 | 2024 | Vanflyta |
| Karyopharm Therapeutics INC. | $17.17 | 2024 | Xpovio |
| Taiho Oncology, INC. | $16.98 | 2025 | |
| Abbvie INC. | $16.72 | 2024 | |
| Novartis Pharmaceuticals Corporation | $15.97 | 2024 | |
| Merck Sharp & Dohme LLC | $15.60 | 2024 | Keytruda |
| Eisai INC. | $14.75 | 2025 | |
| Lilly USA, LLC | $14.11 | 2024 | Jaypirca, Verzenio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Mues listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.